A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease
Oral BPC-157 capsules Standard oral capsules: Contains BPC-157 powder Take on empty stomach Lower bioavailability (only small amount absorbed) Works directly on stomach/gut lining as it passes through Dosing: 500-1,000mcg daily (higher than injectable due to poor absorption) Split into 1-2 doses Take 30 minutes before meals Best for: Stomach ulcers IBS and digestive issues Leaky gut Esophageal issues Oral stable BPC-157 (Arginate or Acetate) Better oral absorption: BPC-157 Arginate or BPC-157 Acetate Modified to resist stomach acid breakdown Higher bioavailability than standard oral More expensive Dosing: 250-500mcg daily (similar to injectable) Can work systemically when absorbed Still best for gut issues How to take: Empty stomach preferred 30 minutes before food With water Don't take with acidic beverages Sublingual administration (under tongue) Some users try sublingual: Hold under tongue for 60-90 seconds May improve absorption vs swallowing No definitive evidence it's better Worth trying if you have capsules How to do it: Open capsule Pour powder under tongue Hold as long as possible Swallow saliva after 60-90 seconds BPC-157 dosing protocols by condition How much to take depends on what you're treating
Diabetes is the leading worldwide cause of blindness, end-stage renal disease, and amputations
Creek DJ, Charman WN, Chiu FC, Prankerd RJ, McCullough KJ, Dong Y, et al
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists Tirzepatide is a once-weekly, subcutaneous injectable peptide with dual agonist activity at both GLP-1 and GIP receptors
